<?xml version='1.0' encoding='utf-8'?>
<document id="28296193"><sentence text="Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin."><entity charOffset="113-125" id="DDI-PubMed.28296193.s1.e0" text="Rosuvastatin" /></sentence><sentence text="Rosuvastatin is a frequently used probe in transporter-mediated drug-drug interaction (DDI) studies"><entity charOffset="0-12" id="DDI-PubMed.28296193.s2.e0" text="Rosuvastatin" /></sentence><sentence text=" This report describes the development of a physiologically based pharmacokinetic (PBPK) model of rosuvastatin for prediction of pharmacokinetic (PK) DDIs"><entity charOffset="98-110" id="DDI-PubMed.28296193.s3.e0" text="rosuvastatin" /></sentence><sentence text=" The rosuvastatin model predicted the observed single (i"><entity charOffset="5-17" id="DDI-PubMed.28296193.s4.e0" text="rosuvastatin" /></sentence><sentence text="v" /><sentence text=" and oral) and multiple dose PK profiles, as well as the impact of coadministration with transporter inhibitors" /><sentence text=" The predicted effects of rifampin and cyclosporine (6"><entity charOffset="26-34" id="DDI-PubMed.28296193.s7.e0" text="rifampin" /><entity charOffset="39-51" id="DDI-PubMed.28296193.s7.e1" text="cyclosporine" /><pair ddi="false" e1="DDI-PubMed.28296193.s7.e0" e2="DDI-PubMed.28296193.s7.e0" /><pair ddi="false" e1="DDI-PubMed.28296193.s7.e0" e2="DDI-PubMed.28296193.s7.e1" /></sentence><sentence text="58-fold and 5" /><sentence text="07-fold increase in rosuvastatin area under the curve (AUC), respectively) were mediated primarily via inhibition of hepatic organic anion-transporting polypeptide (OATP)1B1 (Inhibition constant (Ki ) ∼1"><entity charOffset="20-32" id="DDI-PubMed.28296193.s9.e0" text="rosuvastatin" /></sentence><sentence text="1 and 0" /><sentence text="014 µM, respectively) and OATP1B3 (Ki ∼0" /><sentence text="3 and 0" /><sentence text="007 µM, respectively), with cyclosporine also inhibiting intestinal breast cancer resistance protein (BCRP; Ki ∼0"><entity charOffset="28-40" id="DDI-PubMed.28296193.s13.e0" text="cyclosporine" /></sentence><sentence text="07 µM)" /><sentence text=" The predicted effects of gemfibrozil and its metabolite were moderate (1"><entity charOffset="26-37" id="DDI-PubMed.28296193.s15.e0" text="gemfibrozil" /></sentence><sentence text="88-fold increase in rosuvastatin AUC) and mediated primarily via inhibition of hepatic OATP1B1 and renal organic cation transporter 3" /><sentence text=" This model of rosuvastatin will be useful in prospectively predicting transporter-mediated DDIs with novel pharmaceutical agents in development"><entity charOffset="15-27" id="DDI-PubMed.28296193.s17.e0" text="rosuvastatin" /></sentence><sentence text="" /></document>